Tempus AI (NASDAQ:TEM) CEO Eric Lefkofsky Sells 200,000 Shares of Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 200,000 shares of the stock in a transaction that occurred on Thursday, September 17th. The shares were sold at an average price of $80.57, for a total transaction of $16,114,000.00. Following the transaction, the chief executive officer owned 809,631 shares in the company, valued at approximately $65,231,969.67. This trade represents a 19.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Trading Down 3.1%

NASDAQ:TEM opened at $77.84 on Friday. The company has a market cap of $14.04 billion, a PE ratio of -54.06 and a beta of 3.72. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The company has a 50 day simple moving average of $57.19 and a two-hundred day simple moving average of $52.90. Tempus AI, Inc. has a 12 month low of $40.77 and a 12 month high of $104.32.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. The firm had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period last year, the business posted ($0.22) EPS. Research analysts forecast that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: CEO commentary outlining Tempus AI’s growth strategy and projected Medicare revenue has strengthened confidence that reimbursement expansion could provide a significant new revenue stream. Tempus AI Stock Roars Back 92% From July Low After CEO Lays Out Growth Plan
• Positive Sentiment: Morgan Stanley’s updated outlook reportedly incorporated additional reimbursement-driven revenue potential, helping fuel a sharp weekly advance in TEM shares and reinforcing the bullish growth narrative. Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook
• Positive Sentiment: Trading momentum remains strong: shares have rebounded roughly 92% to 95% from the July low, with market capitalization moving above $14 billion. Above-average volume and elevated call-option activity indicate substantial speculative interest. Tempus AI Stock Is Soaring
• Neutral Sentiment: Analysts and market commentators are assessing whether the recent surge can continue. The rally has improved sentiment, but the sharp move also raises the risk of profit-taking and increased volatility. Strength Seen in Tempus
• Negative Sentiment: Zacks cautioned that recent earnings-estimate revision trends may not support another near-term advance, while brokerages maintain an average “Hold” rating. Tempus also remains unprofitable, making the stock particularly sensitive to valuation concerns and changes in growth expectations. Tempus AI Receives Average Hold Rating

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after acquiring an additional 821,490 shares during the period. Amova Asset Management Americas Inc. increased its holdings in Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after acquiring an additional 821,490 shares in the last quarter. Geode Capital Management LLC raised its stake in Tempus AI by 8.2% during the 4th quarter. Geode Capital Management LLC now owns 1,870,510 shares of the company’s stock worth $110,478,000 after acquiring an additional 141,680 shares during the period. Franklin Resources Inc. raised its stake in Tempus AI by 27.9% during the 4th quarter. Franklin Resources Inc. now owns 1,861,782 shares of the company’s stock worth $109,938,000 after acquiring an additional 405,662 shares during the period. Finally, Lingotto Investment Management LLP lifted its holdings in Tempus AI by 45.9% during the fourth quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company’s stock valued at $67,525,000 after purchasing an additional 359,667 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Analyst Ratings Changes

TEM has been the topic of several recent research reports. Guggenheim increased their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, July 16th. Freedom Capital upgraded shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. HC Wainwright upped their target price on shares of Tempus AI from $56.00 to $66.00 and gave the company a “buy” rating in a report on Friday, September 11th. Roth Capital began coverage on shares of Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price target on the stock. Finally, UBS Group started coverage on shares of Tempus AI in a research note on Wednesday, September 9th. They set a “neutral” rating and a $70.00 price target on the stock. Eleven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $69.33.

About Tempus AI

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.